Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Patients with unknown or negative EGFR mutation status should be treated with the standard chemotherapy first
The majority of the genes in the classifier are either immune-derived or immunomodulatory
miR-34c is a transcriptional target of p53 and potentially new quantitative biomarker of response
First volume of the Cancer Cell Line Encyclopaedia catalogues the world’s cancer cell lines
Launch of Call to Action to improve patient care by enabling access to personalised medicine in Europe
ESMO welcomes the recent EC proposal which will facilitate patient access to innovative treatments on an EU-wide level
Thousands of patients with rare forgotten cancers are paying a high price because doctors lack awareness of their conditions
4th ESMO Conference on Sarcoma and GIST
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
